English
This Project is not specific to Greece. For more details, please visit OpenAIRE Explore.
Link with research outputs.
Please log in first and try again.
DEPSLIT
FunderFrench National Research Agency (ANR)
Funder Contribution €219,960.00
DurationFrom 31 Mar 2014
Project codeANR-13-IS10-0001
Open Access mandatePublications: NoResearch data: No
Identifiers
Description
Early diagnosis and screening of many diseases such as cancer, epidemic influenza, and myocardial infarction (MI), is widely recognized as to greatly increase successful treatment and improve the patient’s quality of life. In 2005, the 58th World Health Assembly approved a resolution urging its member states to give priority to research of early cancer detection. However, significant bottlenecks exist for effective detection at the early stage of a disease. One of the major challenges is the difficulty in detection at the low concentration of cancer biomarkers at the early stage. Traditional physical detection methods are limited by the low signal quality, while chemical detection methods are limited by the low reaction rate. To overcome this obstacle, novel technologies to filter and detect the specific biomarkers need to be developed and implemented. Given the fact that our Consortium members are the first in demonstrating: (1) the development of fabrication protocols for pre-biofunctionalized nanoslit sensors for real-time sensing with spatially resolved reaction kinetics, (2) surface modification scheme for orientated protein sensor immobilization, and (3) ultrafast protein enrichment, demonstrated 105-fold enrichment in 20 seconds (a world record speed), using the concept of molecular damming effect by nanoscale electrodeless dielectrophoresis. By integrating these methodologies developed within the Consortium, we aim to develop a novel integrated biofunctional nanofluidic system for real-time, ultrasensitive, spatially resolved and potentially multiplexed diagnosis for cancer and other disease biomarkers. The multi-disciplinary team assembled here includes expertise from biophysics, micro/nanofluidics, micro/nanofabrication, protein chemistry, surface functionalization, to surface plasmon resonance (SPR) sensors, which are organized to tackle this important challenge, using two model biomarkers: prostate cancer biomarker (prostate specific antigen, or PSA) and cardiovascular biomarker for MI, Troponin I. The outcome of this study should provide practical and low-cost solution to the health care industry and may be extended to general disease biomarker detection and thus benefit the human society in general.
Partners (6)
Start a new DMP in Loading
Early diagnosis and screening of many diseases such as cancer, epidemic influenza, and myocardial infarction (MI), is widely recognized as to greatly increase successful treatment and improve the patient’s quality of life. In 2005, the 58th World Health Assembly approved a resolution urging its member states to give priority to research of early cancer detection. However, significant bottlenecks exist for effective detection at the early stage of a disease. One of the major challenges is the difficulty in detection at the low concentration of cancer biomarkers at the early stage. Traditional physical detection methods are limited by the low signal quality, while chemical detection methods are limited by the low reaction rate. To overcome this obstacle, novel technologies to filter and detect the specific biomarkers need to be developed and implemented. Given the fact that our Consortium members are the first in demonstrating: (1) the development of fabrication protocols for pre-biofunctionalized nanoslit sensors for real-time sensing with spatially resolved reaction kinetics, (2) surface modification scheme for orientated protein sensor immobilization, and (3) ultrafast protein enrichment, demonstrated 105-fold enrichment in 20 seconds (a world record speed), using the concept of molecular damming effect by nanoscale electrodeless dielectrophoresis. By integrating these methodologies developed within the Consortium, we aim to develop a novel integrated biofunctional nanofluidic system for real-time, ultrasensitive, spatially resolved and potentially multiplexed diagnosis for cancer and other disease biomarkers. The multi-disciplinary team assembled here includes expertise from biophysics, micro/nanofluidics, micro/nanofabrication, protein chemistry, surface functionalization, to surface plasmon resonance (SPR) sensors, which are organized to tackle this important challenge, using two model biomarkers: prostate cancer biomarker (prostate specific antigen, or PSA) and cardiovascular biomarker for MI, Troponin I. The outcome of this study should provide practical and low-cost solution to the health care industry and may be extended to general disease biomarker detection and thus benefit the human society in general.
